Center-Authored Papers

Filters: Author is Lenz, Heinz-Josef  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
U
Ulrich CM, Rankin C, Toriola AT, Makar KW, Altug-Teber O, Benedetti JK, Holmes RS, Smalley SR, Blanke CD, Lenz H-J.  2014.  Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304).. Cancer. Abstract
T
Tomblyn MB, Goldman BH, Thomas CR, Benedetti JK, Lenz H-J, Mehta V, Beeker T, Gold PJ, Abbruzzese JL, Blanke CD.  2012.  Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414).. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Abstract
S
Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz H-J, Lee CT, Wilson SS, Benson M, Lerner SP, Tangen CM et al..  2013.  SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Non-Muscle Invasive Bladder Cancer Who Recurred Following at Least Two Prior Courses of Intravesical BCG.. The Journal of urology. Abstract
P
Philip PA, Goldman B, Ramanathan RK, Lenz H-J, Lowy AM, Whitehead RP, Wakatsuki T, Iqbal S, Gaur R, Benedetti JK et al..  2014.  Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO. Cancer. Abstract
B
Bohanes P, Rankin CJ, Blanke CD, Winder T, Ulrich CM, Smalley SR, Rich TA, Martensen JA, Benson AB, Mayer RJ et al..  2015.  Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.. Clinical cancer research : an official journal of the American Association for Cancer Research. 21(7):1583-90. Abstract